Haemostasis · 2009 · 23 citations · 0 references
MedicinePharmacologyPharmacotherapyImmunopathologyInflammationMucosal ImmunologyGastrointestinal InflammationInflammatory Bowel DiseaseInflammatory Bowel Disease CareInflammatory Disease PharmacotherapyMucosal InflammationUlcerative Colitis PharmacotherapyFactor Xiii FunctionFactor Xiii ReplacementInflammatory Bowel Disease TherapyUlcerative Colitis Pathology
Three patients with ulcerative colitis in the active stage demonstrated reduced levels of F XIII activity and F XIII subunit A (61 and 80.3%, respectively). Because of the lack of clinical improvement during conservative therapy, the patients were treated additionally with F XIII concentrate (Fibrogammin HS, Behring, FRG) for 10 days. The substitution resulted in an increase in F XIII activity (144.3%) and F XIII subunit A (238%) as well as in a marked improvement in symptoms.